Back to News
Market Impact: 0.2
Orchestra BioMed Receives $6.1 Million Milestone Payment From Vivasure Acquisition By Haemonetics
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
Orchestra BioMed received a $6.1 million milestone payment triggered by Haemonetics' acquisition of Vivasure Medical. The payment provides a positive, though modest, financial benefit to Orchestra BioMed and reflects value realization from its strategic-partnership technology model.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
HAE0.12
OBIO0.58
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Factbox-Private equity, foreign investors fuel Aussie M&A activity in 2026
- Is Amazon Stock a Buy After Its Best Quarter in Years?
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid